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Abstract 
We report a 20-year-old woman with sickle cell disease (SCD) who presented with a 
severe pulsating headache, nausea, and vomiting. Her history was significant for a past 
thrombotic event during which she had not used anticoagulation therapy as prescribed. 
Her mental status was mildly confused. On funduscopic examination, papilledema and 
retinal hemorrhages were found. Results of a computed tomogram were normal. A 
lumbar puncture demonstrated increased intracranial pressure (60 cm H2O). Magnetic 
resonance venography demonstrated a right sigmoid sinus thrombosis. Although SCD 
has been reported as a cause of thrombotic dural venous sinus events, this case increases 
the knowledge about neurological complications of SCD. The patient was treated with 
low molecular weight heparin, blood transfusions, acetazolamide, and 
methylprednisolone, and her symptoms and signs resolved. 
 
Introduction 
Sickle cell disease (SCD) is a well-known hereditary hematologic disorder of 
hemoglobin. Although SCD has been reported as a cause of dural venous sinus 
thrombosis (DVST) events, this case increases the knowledge about neurological 
complications of SCD [1]. Clinical manifestation of DVST can be life-threatening and  
Case Rep Neurol 2009;1:15–19 
DOI: 10.1159/000216917 
Published online: May 16, 2009  © 2009 S. Karger AG, Basel 
ISSN 1662–680X 
www.karger.com/crn 
 
 
16
cause long-term neurologic deficits [2]. Here, we report a patient with SCD with a current 
sigmoid DVST and a medical history significant for a thrombotic event. She had been 
offered warfarin for the prior event but did not use the correct dosage. 
Case Report 
A 20-year-old woman with homozygous SCD was admitted to the Neurology Department at Başkent 
University in Adana, Turkey, for evaluation of a severe pulsating headache, nausea, and vomiting of 1 
week duration. She had no fever, head trauma, or signs suggesting a respiratory tract infection. She 
complained of photophobia and phonophobia. On examination, her mental status was assessed as 
mildly confused; she subsequently became agitated. Her vital signs were within normal ranges. Results 
of a physical examination were normal. Funduscopic examination revealed papilledema and retinal 
hemorrhages (fig. 1). Her bilateral visual acuity was 3/10 with normal pupillary responses. She did not 
cooperate on vision field test. 
She did not use alcohol or tobacco. Her medical history was significant for a thrombotic event 6 
months earlier that had been treated with a right external iliac venous stent. She had been given 
warfarin, but she did not use it as prescribed. Along with inadequate warfarin use, she also had not 
attended the scheduled follow-ups. 
Remarkable laboratory values (table 1) were: hemoglobin, 6.8 g/dl; hematocrit, 18%; white blood cell 
count, 23,200/mm
3; and International Normalized Ratio (INR), 1.3. The hemoglobin S content was 76%. 
Hypercoagulation tests (i.e., antiphospholipid antibodies, antithrombin-3, and homocysteine levels) 
were negative, but her protein C and S levels were low. A lumbar puncture revealed an opening pressure 
of 60 cm H2O. The cerebrospinal fluid analysis showed: glucose, 60 mg/dl (serum, 87 mg/dl); protein, 18 
mg/dl; no white blood cells; no organisms on Gram staining, and no growth on bacterial cultures. After 
treatment a control lumbar puncture revealed a pressure of 17 cm H2O. 
Results of a brain computed tomogram were normal. Magnetic resonance imaging (MRI) and MR 
venography (MRV) showed a complete thrombosis of the right sigmoid dural venous sinus (fig. 2). She 
was treated with erythrocyte suspension transfusions and low-molecular-weight heparin (LMWH) 
(5,000 U s.c. two times daily; which was subsequently changed to warfarin during hospitalization), with 
methylprednisolone (48 mg daily) and acetazolamide (250 mg three times daily) to decrease the high 
intracranial pressure. Her symptoms resolved 15 days after the beginning of the treatment. During 
hospitalization her photophobia and phonophobia resolved. Her mental status became normal. A 
decision was made to continue therapy with warfarin after discharge lifelong. The patient was followed 
up closely with her parents’ help and INR controls applied. 
Control MRI and MRV examinations performed 3 weeks after the beginning of anticoagulation 
therapy showed an insoluble thrombosis that was still visible but had not progressed. In the 3rd month, 
control MRV was performed and partial flow obtained at the right sigmoid dural venous sinus. Visual 
tests were normal. MRV was repeated six months after discharge and chronic thrombus was seen at the 
right sigmoid dural venous sinus. 
Discussion 
Aseptic DVST is an important complication of SCD with high morbidity and mortality 
[2]. The current case increases the knowledge about neurological complications of SCD. It 
demonstrates the importance of effective anticoagulation therapy in an SCD patient with 
a medical history of a thrombotic event. 
The alteration in mental status and the increased intracranial pressure together with 
headache, vomiting, and visual deficit should lead the physicians to suspect DVST. The 
symptoms and signs of DVST can vary from headache to coma [3]. Headache is the most 
frequently occurring symptom of DVST [4], as was the case in our patient. MRI and MRV 
are crucial for confirming DVST [5]. The sagittal sinus is most commonly involved in 
DVST [4]; however, in our patient, a right sigmoid sinus thrombosis was found.  
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DVST has been associated with infections, dehydration, renal failure, trauma, cancer, 
and hematologic disorders [6, 7]. Increased adherence of sickle cells to the vascular 
endothelia [8], abnormal platelet activation [9], endothelial cell damage and activation of 
cell adhesion molecules [10], low levels of proteins C and S, and increased 
antiphospholipids [11] contribute to thrombogenesis and vascular occlusion in SCD. The 
results of our patient’s tests for hypercoagulation were negative, except for the low levels 
of protein C and S, which SCD patients usually have [12]. 
Unfractionated heparin and LMWH have been reported to be effective in treating 
DVST [13]. We treated our patient with LMWH because of easy administration to 
agitated and mentally confused patients. 
In conclusion, in patients with SCD, careful medical histories should be taken, and 
physicians should be alert to any neurologic signs and symptoms that might be indicative 
of DVST. SCD patients with a history of a thrombotic event should be followed up closely 
to ensure adequate use of anticoagulation therapy. 
 
 
 
Table 1. Patient’s laboratory values 
  Patient’s value  Normal range 
Hb, g/dl  6.8  00.12–17.5 
Htc, %  18  00.36–53 
WBC, /mm
3 23,200  4,500–11,000 
INR 1.3  00.85–1.20 
Hb S, %  76  negative 
Antiphospholipid antibodies  negative  negative 
Antithrombine 3, %  95  00.75–125 
Homocysteine, μmol/l  15  000.5–15 
Protein C, IU/dl  61  00.70–140 
Protein S, IU/l  58  00.72–130 
Serum glucose, mg/dl  87  00.60–105 
Cerebrospinal fluid (CSF) glucose, mg/dl  60  00.40–70 
CSF protein, mg/dl  18  00.15–45 
CSF WBC  negative   
CSF gram stain  no bacteria   
CSF bacterial cultures  negative   
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Fig. 1. Funduscopic examination revealed papilledema and retinal hemorrhages. 
 
 
 
Fig. 2. Complete thrombosis of the right sigmoid dural venous sinus. 
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